Exhibit 10.1


 


 





 


 


Patriot
Scientific Corporation Announces Name Change to “Mosaic ImmunoEngineering Inc.”, 


Stock
Symbol Change and Reverse Stock Split


 


 


Novato,
Calif, December 1, 2020 – Patriot Scientific Corporation ("Patriot") (OTC PINK: PTSC) announced today that it has
changed its name to “Mosaic ImmunoEngineering Inc.”, (the “Company” or “Mosaic”) effective
immediately. In addition, the Company will change its stock symbol on the OTC Market to “CPMV” as described below and
will effect a reverse stock split at a ratio of 1-for-500 (the “Reverse Stock Split”) anticipated to be effective on
or about December 2, 2020 (the “Effective Date”), at which time, the Company’s common stock will trade thereafter
on a post-split adjusted basis. 
The Company’s corporate website is located at www.mosaicie.com.


 


“Mosaic’s lead
development platform has broad potential for the development of therapeutics and vaccines to address a wide range of diseases
including cancer and infectious diseases with a primary focus on immuno-oncology.” stated Steven King, president and
chief executive officer of Mosaic. “Data and recent publications have already garnered positive interest from the
biotechnology and pharmaceutical community which is an important part of creating value for our stockholders. We believe the
name change to Mosaic ImmunoEngineering Inc. and the change in our capital structure are important next steps to making the
Company even more attractive to a broader range of investors. We look forward to sharing more information on our development
plans in the very near future.”


 


About the Reverse Stock Split


 


The Reverse Stock Split will reduce the
number of fully diluted shares of the Company’s common stock currently issued and outstanding, including the number of shares
issuable upon the conversion of Series A and Series B Convertible Voting Preferred Stock, from approximately 4 billion shares to
approximately 8 million shares. Every 500 outstanding shares of common stock, which are outstanding on the anticipated effective
date of December 2, 2020, will be combined into and automatically become one (1) outstanding share of common stock of the Company
without increasing or decreasing the par value of each share of common stock. No fractional share will be issued in connection
with the foregoing combination of the shares pursuant to the Reverse Stock Split. Instead, the Company will issue to the Company’s
stockholders holding a fractional share of common stock one (1) additional share of common stock for each fractional share. Each
stockholder’s percentage ownership interest in the Company and proportional voting power remains virtually unchanged as a
result of the Reverse Stock Split, except for minor changes and adjustments that will result from rounding fractional shares into
whole shares.


 


In connection with the Reverse Stock Split,
the number of authorized shares of common stock was reduced from 600,000,000 shares to 100,000,000 shares.


 


Stockholders who are holding their shares
in electronic form at a brokerage firm, bank or other nominee will automatically have their positions adjusted to reflect the Reverse
Stock Split.


 


Stockholders holding paper certificates
may (but are not required to) send the certificates to the Company’s transfer agent at the address given below. The transfer
agent will issue a new share certificate reflecting the Name Change and terms of the Reverse Stock Split to each requesting stockholder.


 


Issuer
Direct Corporation


1981
Murray Holladay Rd., Suite 100


Salt
Lake City, UT 84117


Tel:
+1.800.272.9294


Fax:
+1.801.277.3147


 


Please
contact Issuer Direct Corporation for further information, related costs and procedures before sending any certificates.


 


 


 






    	 	1	 



     

    

 


New Trading Symbol and CUSIP


 


Our common stock is quoted on the OTC Markets
Pink tier under the trading symbol "PTSC."  On the Effective Date of the Reverse Stock Split, our common stock will
be quoted on the OTC Markets Pink tier on a post-split adjusted basis under the symbol “PTSCD” for 20 business days,
after which time the symbol will change to our new trading symbol, CPMV. The new trading symbol, CPMV, was derived from CowPea
Mosaic Virus, which is central to the Company’s core nanotechnology platform.


 


On the Effective Date of the Reverse Stock
Split, the CUSIP number of our common stock will change to 61945M101.


 


About Mosaic ImmunoEngineering Inc.


 


Mosaic ImmunoEngineering Inc. is a development-stage
biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer
and infectious diseases. Mosaic’s core technology platform is based on Cowpea Mosaic Virus (“CPMV”) which is
non-infectious to humans or other animals but upon intra-tumoral administration, elicits a strong innate immune response resulting
in potent anti-tumor activity against the primary and distant tumor sites. The broad potential of our lead candidate, MI-O-101,
for the treatment of many different types of cancer and potential combination therapies continue to be supported by numerous publications
and grant funding through our university collaborators. In addition, the core technology has a potential application as part of
a modular vaccine platform which has already generated promising data in both cancer and infectious disease preclinical models,
including COVID-19. The vaccine research is currently being performed by one of our co-founders and is funded by the National Science
Foundation with viral neutralization testing being performed by the National Institute of Allergy and Infectious Diseases (NIAID).
For additional information about Mosaic, please visit MosaicIE.com.


 


Forward-Looking Statements


 


This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995
and other Federal securities laws. For example, we are using forward-looking statements when we discuss Mosaic’s future operations
and its ability to successfully advance the product candidates; the nature, strategy and focus of Mosaic’s business; and
the development and commercial potential and potential benefits of any of Mosaic’s product candidates. Mosaic may not actually
achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements
and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and
are based on Mosaic’s current expectations, they are subject to various risks and uncertainties and actual results, performance
or achievements of these forward-looking statements could differ materially from those described in or implied by the statements
in this press release, including: the uncertainties associated with raising sufficient capital and the requirement for significant
additional capital to advance these product candidates, which may not be available on favorable terms or at all; advancing Mosaic's
multiple products into clinical trials, the clinical development and regulatory approval of Mosaic's product candidates, including
potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier preclinical studies
of Mosaic's product candidates may not be predictive of future results; risks related to business interruptions, including but
not limited to, the outbreak of COVID-19 coronavirus, which could seriously harm Mosaic’s financial condition and increase
its costs and expenses. The foregoing review of important factors that could cause actual events to differ from expectations should
not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including
the risks discussed in Mosaic's filings with the Securities and Exchange Commission. Except as otherwise required by law, Mosaic
disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof,
whether, as a result of new information, future events or circumstances or otherwise.


 


Contact:

Jay Carlson, Investor Relations


Mosaic ImmunoEngineering Inc.


info@mosaicie.com


 


 


 


 



    	 	2